Assessing Immunogenicity in the Presence of Excess Protein Therapeutic Using Immunoprecipitation and Quantitative Mass Spectrometry
Authors:
- 15 August 2008
- journal article
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 80 (18) , 6907-6914
Abstract
The administration of biological protein therapeutics can lead to an unwanted immune response resulting in the generation of anti-drug antibodies (ADA) with potentially harmful clinical consequences. Hence, to develop safe and efficacious biotherapeutics, the immunogenic potential needs to be examined during the development phase. Current assay technologies measuring ADAs are subject to interference by high circulating concentrations of the protein therapeutic, raising concerns about data reliability since protein therapeutic-free washout samples are not always available. Herein, we report the development and characterization of a magnetic bead based immunoprecipitation method followed by quantitative LC/MS to determine ADA in human and cynomolgus serum in the presence of high circulating concentrations of the protein therapeutic. Available ADA binding sites are saturated by the addition of excess therapeutic followed by magnetic bead based protein G isolation of IgG antibodies and their bound antigens before elution and digestion. Peptides of the target therapeutic proteins are then quantified by LC/MS using stable isotope labeled standards inferring the presence of total ADA. This approach complements established methodologies for the assessment of immunogenicity responses and currently supports clinical programs addressing the safety and tolerability of human growth hormone analogues.Keywords
This publication has 23 references indexed in Scilit:
- Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISARegulatory Toxicology and Pharmacology, 2007
- A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugsNature Biotechnology, 2007
- Scientific and regulatory considerations on the immunogenicity of biologicsTrends in Biotechnology, 2006
- Immunogenicity Testing by Electrochemiluminescent Detection for Antibodies Directed against Therapeutic Human Monoclonal AntibodiesClinical Chemistry, 2005
- Rationally Engineered Therapeutic Proteins with Reduced ImmunogenicityThe Journal of Immunology, 2005
- Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology productsJournal of Immunological Methods, 2004
- Anti-Erythropoietin Antibodies and Pure Red Cell AplasiaJournal of the American Society of Nephrology, 2004
- Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicalsJournal of Immunological Methods, 2003
- Immunogenicity of therapeutic proteins: Clinical implications and future prospectsClinical Therapeutics, 2002
- Pure Red-Cell Aplasia and Recombinant ErythropoietinNew England Journal of Medicine, 2002